BioLineRx Stock Market Outlook
| BLRX Stock | USD 3.35 0.31 10.20% |
This sentiment measure is descriptive rather than personalized advice and should be used with other evidence before acting on it. Around 55% of recent sentiment around BioLineRx has been mildly constructive over the recent sample. Taken on its own, that leaves the current sentiment reading for BioLineRx close to neutral at this time.
Investor Comfort Level
PanicConfidence
55 · Impartial
Elasticity to Hype and News Sentiment
BioLineRx news sentiment reading of 50% (mixed) tracks how media and analyst commentary are framing the investment case. Cross-checking that reading with earnings momentum and price action helps confirm whether the narrative is running ahead of or behind the business.
Given a 90-day horizon, with a moderate risk tolerance, the model output for BioLineRx is 'Strong Sell'. Our automated recommendation for BioLineRx is built from quantitative evidence and fundamental indicators. The analysis combines quantitative signals with investor-specific risk parameters. The recommendation evaluates return potential against downside risk within defined investment parameters. Complementing automated signals with independent research strengthens the broad analytical foundation.
BioLineRx |
Run BioLineRx Outlook Model
Our BioLineRx outlook engine provides a data-driven supplement to the analyst consensus on BioLineRx. Macroaxis has no vested interest in BioLineRx or any other instrument analyzed here. Multiple quantitative inputs drive the BioLineRx's signal across different market conditions. Combining algorithmic signals with independent analysis supports more informed decisions.
How This Model Works
The recommendation output for BioLineRx is a model-based view that converts the selected horizon and risk profile into a standardized reading of the current evidence.
- Inputs - valuation signals, price behavior, volatility, liquidity, sentiment, and analyst coverage when available
- Current setup - Three Months with a risk setting described as I am an average risk taker
- Limits - the model does not account for taxes, outside holdings, concentration constraints, or investor-specific mandates
Use the output as structured decision support and pair it with your own research, portfolio context, and any professional advice you rely on.
Time Horizon
Risk Tolerance
Strong Sell
Market Performance | Mild | Details | |
Volatility | Very High | Details | |
Current Valuation | Above Model Estimate | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
BioLineRx's current outlook reflects a cautious setup, where negative margins limit earnings-based valuation support. The model's 'Strong Sell' signal reflects persistent headwinds that outweigh the offsetting factors in the model. For the selected horizon, BioLineRx yields Mean Deviation of 2.91, Semi Deviation of 3.89, and Standard Deviation of 4.64, which weigh on the current risk-reward outlook.The quantitative analytical reading for BioLineRx blends historical performance patterns with current market conditions and the analyst and expert consensus to frame the risk-reward profile. For additional context on this micro-cap stock, review the full set of BioLineRx reported fundamentals, including cash per share ttm, and the relationship between the price to sales ttm and short ratio ttm. BioLineRx reports a number of shares shorted of 154.75 K. Its market performance and financial distress probability provide additional context.
Recent Events and Market Context
The events below reflect recent headlines associated with BioLineRx. Not all items directly affect the outlook — they are included to show the broader information environment that can shape sentiment and trading behavior.
Current Analysts Advice
The current analyst picture for BioLineRx reflects a rolling average of published recommendations from research firms, banks, and independent analysts. In practice, the consensus view serves as a sentiment benchmark rather than a direct buy-or-sell command.
Analyst target prices for BioLineRx are derived from individual forecasts, so they can differ materially from Macroaxis recommendation signals. The cleaner workflow is to treat the consensus target as one input in a broader decision process.
Returns Distribution Density
Plotting BioLineRx's daily returns in a distribution reveals the day-to-day behavior of BioLineRx. It shows how returns are grouped around the average and how often large swings occur. Value At Risk and Upside Potential quantify both the risk and the reward. Value At Risk shows the worst-case boundary and Upside Potential shows the best-case boundary.
| Mean Return | 0.32 | Value At Risk | -5.17 | Potential Upside | 6.29 | Standard Deviation | 4.64 |
Return Density |
| Distribution |
Risk management for BioLineRx depends on quantifying the frequency and magnitude of extreme moves. The distribution chart below makes that clear for BioLineRx. Portfolio managers weigh the trade-offs across risk-return profiles. Return distribution analysis highlights the frequency and magnitude of extreme price moves in BioLineRx.
Key Drivers of Volatility and Market Exposure
Market risk ties BioLineRx to macro cycles, whereas company or sector-specific developments represent independent drivers. Volatility metrics help measure this balance. BioLineRx reported a Downside Deviation of 4.31, a Mean Deviation of 2.91, and a Semi Deviation of 3.89.
α | Alpha over Dow Jones | 0.31 | |
β | Beta against Dow Jones | -0.1877 | |
σ | Overall volatility | 4.68 | |
Ir | Information ratio | 0.06 |
Fundamentals Vs Peers
BioLineRx is measured here against stocks with similar revenue scale, margin profile, and capital structure. The comparison below reveals whether BioLineRx generates superior or inferior returns relative to similar stocks. Divergence between BioLineRx's valuation multiples and its peer group flags either mispricing or a structural difference in quality. Direct comparison with similar stocks converts BioLineRx's standalone financial data into an actionable relative signal.
| Better Than Average | Worse Than Average | Compare BioLineRx to competition |
Note: Insider Trading [view details]
Market Momentum
BioLineRx momentum reading - RSI 64 (mildly bullish), beta -0.1877 (negative-beta) - helps distinguish trend continuation from fading conviction. Comparing these readings with volume and earnings revisions strengthens the signal since the signal is more company-driven than market-linked.
Recommendation Framework, Assumptions & Editorial Oversight
The model output for BioLineRx reflects the current horizon and risk settings, refreshes as underlying data changes, and is intended to organize evidence rather than replace investor judgment. Current model inputs for BioLineRx include ROE of -11.01%, market cap of 13.68 million. 
BioLineRx metrics draw on periodic company reporting and market reference feeds, standardized for cross-period comparison. The model combines valuation, price behavior, volatility, and sentiment into a standardized quantitative view.
Editorial Review & Methodology Oversight
Role: Member of Macroaxis Editorial Board
Finance background: Gabriel is a young entrepreneur and writes predominantly on the business, technology, and finance sector. He likes to analyze different equity instruments across a wide range of industries focusing primarily on consumer products and evolving technologies.
Oversight scope: Reviews recommendation-framework framing, source assumptions, and disclosure language.